Literature DB >> 29471779

Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop.

B Lenz1, A Braendli-Baiocco1, J Engelhardt2, P Fant3, H Fischer1, S Francke4, R Fukuda5, S Gröters6, T Harada7, H Harleman8, W Kaufmann9, S Kustermann1, T Nolte10, X Palazzi11, G Pohlmeyer-Esch10, A Popp12, A Romeike13, A Schulte14, B Silva Lima15, L Tomlinson11, J Willard16, C E Wood17, M Yoshida18.   

Abstract

Lysosomes have a central role in cellular catabolism, trafficking, and processing of foreign particles. Accumulation of endogenous and exogenous materials in lysosomes represents a common finding in nonclinical toxicity studies. Histologically, these accumulations often lack distinctive features indicative of lysosomal or cellular dysfunction, making it difficult to consistently interpret and assign adverse dose levels. To help address this issue, the European Society of Toxicologic Pathology organized a workshop where representative types of lysosomal accumulation induced by pharmaceuticals and environmental chemicals were presented and discussed. The expert working group agreed that the diversity of lysosomal accumulations requires a case-by-case weight-of-evidence approach and outlined several factors to consider in the adversity assessment, including location and type of cell affected, lysosomal contents, severity of the accumulation, and related pathological effects as evidence of cellular or organ dysfunction. Lysosomal accumulations associated with cytotoxicity, inflammation, or fibrosis were generally considered to be adverse, while those found in isolation (without morphologic or functional consequences) were not. Workshop examples highlighted the importance of thoroughly characterizing the biological context of lysosomal effects, including mechanistic data and functional in vitro readouts if available. The information provided here should facilitate greater consistency and transparency in the interpretation of lysosomal effects.

Entities:  

Keywords:  PEGylated; adversity; alpha-2u globulin; antisense oligonucleotides; hazard; iron; lipofuscin; lysosomal accumulation; phospholipidosis; risk assessment; risk–benefit

Mesh:

Year:  2018        PMID: 29471779     DOI: 10.1177/0192623317749452

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  4 in total

1.  Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption.

Authors:  Manoe J Janssen; Tom T G Nieskens; Tessa A M Steevels; Pedro Caetano-Pinto; Dirk den Braanker; Melissa Mulder; Yolanda Ponstein; Shaun Jones; Rosalinde Masereeuw; Cathaline den Besten; Martijn J Wilmer
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-06       Impact factor: 8.886

2.  Use of 3D Human Liver Organoids to Predict Drug-Induced Phospholipidosis.

Authors:  Ji-Young Lee; Hyo-Jeong Han; Sang-Joon Lee; Eun-Ho Cho; Han-Byul Lee; Ju-Hyung Seok; Hee Seon Lim; Woo-Chan Son
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

3.  Atypical Antipsychotic Lumateperone Effects on the Adrenal Gland With Possible Beneficial Effect of Quercetin Co-administration.

Authors:  Hala El-Haroun; Suzy Fayez Ewida; Wael M Y Mohamed; Manar Ali Bashandy
Journal:  Front Physiol       Date:  2021-06-29       Impact factor: 4.566

4.  Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.

Authors:  Sebastian Peters; Eva Wirkert; Sabrina Kuespert; Rosmarie Heydn; Siw Johannesen; Anita Friedrich; Susanne Mailänder; Sven Korte; Lars Mecklenburg; Ludwig Aigner; Tim-Henrik Bruun; Ulrich Bogdahn
Journal:  Pharmaceutics       Date:  2022-01-15       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.